Theraclion: Results for the First Half of 2024 and Strategic Outlook

Theraclion, a company specializing in non-invasive ultrasound therapy, continues its efforts to increase its presence in the American and Asian markets. During the first half of 2024, major progress was made, notably thanks to the completion of treatments in the pivotal study in the United States, essential for FDA approval. The company's flagship product SONOVEIN achieved a clinical efficacy of 98.3%.

However, revenue for the period fell by 82% to €442k, mainly due to lower equipment sales. Despite an improvement in gross margin to 61%, net income remains in deficit at €2,363k, although reduced by 4.6% compared to 2023.

Theraclion plans to begin targeted marketing in Europe and the Middle East as early as 2025, with an ambitious revenue target. The company also plans to increase its cash flow through various contributions, in order to support its growth strategy.